

Raewyn J Hopkins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8219180/publications.pdf>

Version: 2024-02-01

62
papers

1,239
citations

394286

19
h-index

395590

33
g-index

62
all docs

62
docs citations

62
times ranked

1878
citing authors

#	ARTICLE	IF	CITATIONS
1	Incorporating Baseline Lung Function in Lung Cancer Screening. <i>Chest</i> , 2021, 159, 1664-1669.	0.4	6
2	Chr15q25 genetic variant (rs16969968) independently confers risk of lung cancer, COPD and smoking intensity in a prospective study of high-risk smokers. <i>Thorax</i> , 2021, 76, 272-280.	2.7	12
3	The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 699-707.	1.0	12
4	Mevalonate signaling, COPD and cancer: the statins and beyond. <i>Journal of Investigative Medicine</i> , 2019, 67, 711-714.	0.7	8
5	Multi-analyte assays and early detection of common cancers. <i>Journal of Thoracic Disease</i> , 2018, 10, S2165-S2167.	0.6	8
6	Identifying Patients for Whom Lung Cancer Screening Is Preference-Sensitive. <i>Annals of Internal Medicine</i> , 2018, 169, 822.	2.0	1
7	Reply: The Western Diet: A Smoking Gun for Chronic Obstructive Pulmonary Disease and Asthma?. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1241-1241.	1.5	1
8	Chronic obstructive pulmonary disease (COPD) and lung cancer screening. <i>Translational Lung Cancer Research</i> , 2018, 7, 347-360.	1.3	69
9	Is the "Western Diet" a New Smoking Gun for Chronic Obstructive Pulmonary Disease?. <i>Annals of the American Thoracic Society</i> , 2018, 15, 662-663.	1.5	14
10	A new alphabet for COPD care: where "E" stands for España. <i>European Respiratory Journal</i> , 2017, 49, 1601970.	3.1	7
11	Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk. Results from the National Lung Screening Trial—American College of Radiology Imaging Network Cohort. <i>Annals of the American Thoracic Society</i> , 2017, 14, 392-402.	1.5	47
12	Characteristics of sarcoidosis in Maori and Pacific Islanders. <i>Respirology</i> , 2017, 22, 360-363.	1.3	7
13	The Mevalonate Pathway and Innate Immune Hyper-Responsiveness in the Pathogenesis of COPD and Lung Cancer: Potential for Chemoprevention. <i>Current Molecular Pharmacology</i> , 2017, 10, 46-59.	0.7	18
14	Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model. <i>International Journal of Oncology</i> , 2016, 49, 361-370.	1.4	20
15	The Relationship between Dietary Fiber Intake and Lung Function in the National Health and Nutrition Examination Surveys. <i>Annals of the American Thoracic Society</i> , 2016, 13, 643-650.	1.5	49
16	The Gut—"Liver"—Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 161-169.	1.4	81
17	Lung Cancer Susceptibility, Ethnicity, and the Benefits of Computed Tomography Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1394-1396.	2.5	1
18	Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1060-1067.	2.5	115

#	ARTICLE	IF	CITATIONS
19	Mortality Reduction, Overdiagnosis, and the Benefit-to-Harm Ratio of Computed Tomography Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 398-399.	2.5	3
20	Primary and Secondary Prevention of Chronic Obstructive Pulmonary Disease: Where to Next?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 839-840.	2.5	8
21	A review of the Hispanic paradox: time to spill the beans?. <i>European Respiratory Review</i> , 2014, 23, 439-449.	3.0	24
22	Statins Reduce Respiratory Complications of COPD. <i>American Journal of Medicine</i> , 2014, 127, e7.	0.6	0
23	Statins as adjunct therapy in COPD: how do we cope after STATCOPE?. <i>Thorax</i> , 2014, 69, 891-894.	2.7	24
24	High Dietary Fiber Lowers Systemic Inflammation: Potential Utility in COPD and Lung Cancer. <i>American Journal of Medicine</i> , 2014, 127, e13.	0.6	6
25	Interleukin-6 and statin therapy: potential role in the management of COPD. <i>Respiratory Research</i> , 2013, 14, 74.	1.4	13
26	Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. <i>Cancer</i> , 2013, 119, 1761-1761.	2.0	5
27	Is 20% of a loaf enough?. <i>Cancer</i> , 2013, 119, 2815-2815.	2.0	2
28	Screening with low-dose computed tomography: Response to The American Association of Thoracic Surgery guidelines. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2013, 145, 307-308.	0.4	3
29	Statin Use in Pneumonia. <i>American Journal of Medicine</i> , 2013, 126, e11-e12.	0.6	8
30	Statins Reduce Lung Inflammation by Promoting the Clearance of Particulate Matter From Lung Tissues. <i>Chest</i> , 2013, 144, 358-359.	0.4	4
31	Stage Shift in Computed Tomography Screening: Possible Role of Indolent Cancers, "Histology Shift," and Overdiagnosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 1034-1035.	2.5	7
32	Statins and Small Airways Disease in COPD. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 501-501.	1.4	4
33	Incorporating genomic data into multivariate risk models for lung cancer. <i>Genetics in Medicine</i> , 2013, 15, 667-668.	1.1	7
34	Update on the potential role of statins in chronic obstructive pulmonary disease and its co-morbidities. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 533-544.	1.0	28
35	Predictive Accuracy of the Liverpool Lung Project Risk Model. <i>Annals of Internal Medicine</i> , 2013, 158, 568.	2.0	0
36	Estimating Overdiagnosis of Lung Cancer. <i>Annals of Internal Medicine</i> , 2013, 158, 635.	2.0	12

#	ARTICLE	IF	CITATIONS
37	Targeted CT Image Screening and Its Effect on Lung Cancer Detection Rate. <i>Chest</i> , 2013, 144, 1419-1420.	0.4	11
38	CT screening for lung cancer: Figure 1. <i>Thorax</i> , 2012, 67, 650.3-651.	2.7	1
39	Lung Cancer Risk Prediction to Select Smokers for Screening CTâ€™Letter: Figure 1.. <i>Cancer Prevention Research</i> , 2012, 5, 697-698.	0.7	14
40	Diagnosing COPD and targeted lung cancer screening: Figure 1â€™. <i>European Respiratory Journal</i> , 2012, 40, 1063-1064.	3.1	32
41	Genetic Predisposition to Chronic Obstructive Pulmonary Disease and/or Lung Cancer: Important Considerations When Evaluating Risk. <i>Cancer Prevention Research</i> , 2012, 5, 522-527.	0.7	41
42	Chronic Obstructive Pulmonary Disease Detection During Lung Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 664.	3.8	1
43	Joint Effect of Single-Nucleotide Polymorphisms and Smoking Exposure in Chronic Obstructive Pulmonary Disease Risk. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 683-683.	2.5	4
44	A Clinical Practice Guideline Update on the Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2012, 156, 68.	2.0	15
45	Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 35-40.	2.5	63
46	Computed Tomographic Screening for Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1320.	3.8	9
47	Prevalence of asthma and atopy in sarcoidosis. <i>Respirology</i> , 2012, 17, 285-290.	1.3	14
48	The sixâ€™minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. <i>Respirology</i> , 2012, 17, 647-652.	1.3	27
49	FAM13A locus in COPD is independently associated with lung cancer – evidence of a molecular genetic link between COPD and lung cancer. <i>The Application of Clinical Genetics</i> , 2011, 4, 1.	1.4	45
50	Genetic evidence linking lung cancer and COPD: a new perspective. <i>The Application of Clinical Genetics</i> , 2011, 4, 99.	1.4	23
51	GSTM1 null genotype in COPD and lung cancer: evidence of a modifier or confounding effect?. <i>The Application of Clinical Genetics</i> , 2011, 4, 137.	1.4	9
52	How the genetics of lung cancer may overlap with COPD. <i>Respirology</i> , 2011, 16, 1047-1055.	1.3	61
53	GWAS in lung disease. <i>Thorax</i> , 2011, 66, 1012-1013.	2.7	3
54	COPD and Lung Cancer Linked at a Molecular Genetic Level. <i>Chest</i> , 2011, 140, 266-267.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Individual and Cumulative Effects of GWAS Susceptibility Loci in Lung Cancer: Associations after Sub-Phenotyping for COPD. PLoS ONE, 2011, 6, e16476.	1.1	83
56	Possible Role of Statins in COPD-Related Pulmonary Hypertension. Chest, 2010, 137, 1250-1251.	0.4	4
57	Smoking cessation: the potential role of risk assessment tools as motivational triggers. Postgraduate Medical Journal, 2010, 86, 26-33.	0.9	34
58	Statins Use and Pneumonia. Chest, 2010, 137, 1249.	0.4	0
59	Link between COPD and lung cancer. Respiratory Medicine, 2010, 104, 758-759.	1.3	29
60	Lung Cancer Susceptibility Model Based on Age, Family History and Genetic Variants. PLoS ONE, 2009, 4, e5302.	1.1	47
61	Recent air travel and venous thromboembolism resulting in hospital admission. Respiriology, 2006, 11, 75-79.	1.3	12
62	Lower occurrence of idiopathic pulmonary fibrosis in Maori and Pacific Islanders. Respiriology, 2006, 11, 467-470.	1.3	10